Pharmacokinetics and metabolism of intravenous pirfenidone in sheep

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 2, 2008, Pages 119-126

  Bruss, Michael L ^a   Stanley, Scott D ^a   Margolin, Solomon B ^b   Giri, Shri N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Marnac Inc   (United States)

Author keywords

Metabolism; Pharmacokinetics; Pirfenidone; Sheep

Indexed keywords

ACETOXYPIRFENIDONE; ANTIFIBROTIC AGENT; CARBOXYPIRFENIDONE; DRUG METABOLITE; HYDROXYPIRFENIDONE; HYDROXYPIRFENIDONE GLUCURONIDE; PIRFENIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE WALL; LUNG PARENCHYMA; MASS SPECTROMETRY; NONHUMAN; QUANTITATIVE ANALYSIS; SCINTILLATION SPECTROMETRY; SHEEP; SINGLE DRUG DOSE; SPECTROFLUOROMETRY;

ANIMALS; FEMALE; INJECTIONS, INTRAVENOUS; PYRIDONES; SHEEP; TISSUE DISTRIBUTION;

EID: 42149193768     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.595     Document Type: Article

References (18)

1. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1995; 125: 779-785.
2. Kehrer JP, Margolin SB. Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol Lett 1997; 90: 125-132.
3. Iyer SN, Margolin SB, Hyde DM, Giri SN. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin hamster model. Exp Lung Res 1998; 24: 119-132.
4. Tada S, Nakamuta M, Enjoji M, et al. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharm Physiol 2001; 28: 522-527.
5. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001; 133:687-694.
6. Raghu. G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999; 159: 1061-1069
7. Walker JE, Margolin SB. Pirfenidone for chronic progressive multiple sclerosis. Mult Scler 2002; 7: 305-312.
8. Walker JE, Giri SN, Margolin SB. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult Scler 2005; 11: 149-158.
9. Taniyama M, Ohbayashi S, Narita M, et al. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. Eur J Clin Pharmacol 1997; 52: 77-78.
10. Babovic-Vuksanovic D, Widemann BC, Dombi E, et al. Phase I trial of pirfenidone in children with neurofibromatosis I and plexiform neurofibromas. Pediatr Neurol 2007; 36: 293-300.
11. Giri SN, Wang Q, Xie Y, et al. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 2002; 23: 203-211.
12. Bruss ML, Margolin SB, Giri SN. Pharmacokinetics of orally administered pirfenidone in male and female beagles. J Vet Pharmacol Ther 2005; 27: 361-367.
13. Radostits OM, Gay CC, Blood DC, Hinchcliff KW. Veterinary Medicine: A Textbook of the Diseases of Cattle, Sheep, Pigs, Goats and Horses, 9th edn. W. B. Saunders: Edinburgh, 1999; 355-358, 1184-1191, 1661-1665.
14. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. Williams and Wilkins: Baltimore, 1995; 424-442, 469-470.
15. Shargel L, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics, 3rd edn. Appleton and Lange: Stamford, CT, 1993; 299-301.
16. Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary comparative paradigm. Drug Metab; Rev 1984; 15: 1071-1121.
17. Higa HH, Butor C, Diaz S, Varki A. O-acetylation and de-O-acetylation of sialic acids. O-acetylation of sialic acids in the rat live Golgi apparatus involves an acetyl intermediate and essential histidline and lysine residues - a transmembrane reaction? J Biol Chem 1989; 264: 19427-19434.
18. Hein DW, Doll MA, Fretland AJ, et al. Rodent models of the human acetylation polymorphism: comparisons of recombinant acetyltransferases. Mutat Res 1997; 376: 101-106.